The combination of several therapeutic approaches with various mechanisms can be feasible option for effectively treating cancers with combined or synergistic impacts. Small interference of RNA was a strong technique with a feasible therapeutic option to silence genes targeted in a number of diseases. A number of different therapeutics based on siRNA have established for treatment of diseases effectively. However, there cannot be easy crossing of cell membranes in siRNA due to the involvement of negative charge and there is a delay in downstream effects. This is in comparison with the conventional therapeutics based on protein or small molecule.
for being successful in clinically applying siRNA, there is a requirement to be effective in delivering vehicles. This is crucial for overcoming several barriers in the cell. In addition, anti-cancer drug effect of small molecule is fast in comparison with siRNA. This is specific in the process of intra-cellular uptake. Simultaneously, nanocarriers will be targeting the drugs while lowering the side effect. Therefore, the set of newly emerging therapy based on siRNA with traditional procedures of chemotherapy can be considered advantageous.
Until yet, a number of promising systems for the purposes of co-delivery are established on the basis of silica, liposomal and polymeric based cationic NPs. When compared, non-viral vectors based on polymer have major benefits in comparison with cationic lipids. These advantages are specific to physiological stability, large scale production, convenience and safety. There has been an investigation of several natural and synthetic cationic polymers as carriers of siRNA or gene. These include chitosan, polylysine and polyethyleneimine.